By Colin Kellaher
Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a certain type of brain tumor.
Shares of the Durham, N.C., company were recently changing hands at $4.99, up 14%, after touching a 52-week high of $5.12 early in the session.
Chimerix is seeking FDA approval of dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, a form of high-grade glioma with few treatment options beyond palliative care.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease. The designation shortens the review period.
Chimerix said the FDA has set a target action date of Aug. 18, adding that the agency doesn't currently plan to hold an advisory committee meeting to discuss the application.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:38 ET (15:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.